Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23

Chiara Degirolamo, Carlo Sabbà, Antonio Moschetta

Research output: Contribution to journalArticle

153 Scopus citations

Abstract

The endocrine fibroblast growth factors (FGFs), FGF19, FGF21 and FGF23, are critical for maintaining whole-body homeostasis, with roles in bile acid, glucose and lipid metabolism, modulation of vitamin D and phosphate homeostasis and metabolic adaptation during fasting. Given these functions, the endocrine FGFs have therapeutic potential in a wide array of chronic human diseases, including obesity, type 2 diabetes, cancer, and kidney and cardiovascular disease. However, the safety and feasibility of chronic endocrine FGF administration has been challenged, and FGF analogues and mimetics are now being investigated. Here, we discuss current knowledge of the complex biology of the endocrine FGFs and assess how this may be harnessed therapeutically.

Original languageEnglish (US)
Pages (from-to)51-69
Number of pages19
JournalNature Reviews Drug Discovery
Volume15
Issue number1
DOIs
StatePublished - Jan 1 2016

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Fingerprint Dive into the research topics of 'Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23'. Together they form a unique fingerprint.

  • Cite this